Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
Toray Industries, Inc
Shanghai Junshi Bioscience Co., Ltd.
Eli Lilly and Company
Nektar Therapeutics
Case Comprehensive Cancer Center